ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts have also recently weighed in on ANIP. Weiss Ratings upgraded ANI Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, June 23rd. Guggenheim reaffirmed a "buy" rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Canaccord Genuity Group started coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They issued a "hold" rating and a $91.00 price objective for the company. Finally, Zacks Research lowered ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 14th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $106.83.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $78.25 on Friday. The firm has a fifty day simple moving average of $81.02 and a two-hundred day simple moving average of $79.37. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals has a twelve month low of $70.15 and a twelve month high of $99.50. The company has a market capitalization of $1.78 billion, a PE ratio of 19.81 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analysts' expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company's revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period last year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts expect that ANI Pharmaceuticals will post 8.03 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, Director Thomas Haughey sold 2,000 shares of the firm's stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the sale, the director directly owned 38,878 shares of the company's stock, valued at $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the business's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the transaction, the chief financial officer owned 177,543 shares in the company, valued at approximately $15,268,698. This represents a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 88,029 shares of company stock valued at $6,954,472. Company insiders own 8.10% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company's stock worth $103,022,000 after acquiring an additional 27,598 shares in the last quarter. Penn Capital Management Company LLC lifted its stake in shares of ANI Pharmaceuticals by 2,058.9% in the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company's stock valued at $10,858,000 after purchasing an additional 131,030 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $2,487,000. Artemis Investment Management LLP bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $1,706,000. Finally, CenterBook Partners LP purchased a new stake in ANI Pharmaceuticals in the fourth quarter worth $1,518,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source